TrialLancet (London, England)2023

Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): a multicentre, randomised, open-label, phase 3 trial.

Sumanta Kumar Pal et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.